Update: SpaceX Shares Look 'Cheap and Getting Cheaper,' Morgan Stanley Says
MT newswire2026/10/05 16:4312:43 PM EDT, 10/05/2026 (MT Newswires) -- (Updates with additional details in the third and fourth paragraphs.) SpaceX (SPCX) shares are "cheap and getting cheaper," Morgan Stanley analyst Adam Jonas said in a note Sunday. The shares have hovered around $150 per share since early August, and at $159, investors can take advantage of an opportunity to buy shares that, "while expensive on any trailing metric, look unusually cheap on the forward," Jonas said. The company trades at about 30 times estimated 2028 enterprise value to earnings before interest and taxes, compared with about 16 times for other mega-cap AI enablers, the note said. However, when adjusted for year-over-year growth, it trades at 0.3 times, lower than the mega-cap median, the note added. Morgan Stanley maintained its overweight rating and $300 price target on SpaceX. The company's shares rose over 5% in the session. Price: 167.05, Change: +8.08, Percent Change: +5.09
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SQM.US Q3 profit misses expectations; lithium price declines but demand outlook remains “encouraging”
SQM.US still reports seeing "encouraging" potential demand trends.
Mizuho: Consecutive system outages in the US trigger stockpiling surge! With short-term demand boosted, Costco (COST.US) sales momentum is expected to remain strong.
According to a report by Mizuho Securities analysts, following a series of recent system failures in the United States, consumers have started stockpiling essential goods, leading to a short-term surge in demand for Costco, a members-only retailer.

Biogen (BIIB.US) announces mid-stage trial data for early Alzheimer's candidate drug diranersen: significant slowing of clinical decline over two years
Biogen has released the latest interim clinical trial data for its early-stage Alzheimer's disease candidate drug, diranersen.

Nvidia Acting CEO Kress Reassures the Market: No Customer Loss and No Employee Exodus
Nvidia released its first quarterly financial report since Jensen Huang's resignation, after which Colette Kress told the media that major client demand has not been affected and the workforce remains stable, emphasizing that "everything is business as usual." The company's share price rose over 3% after hours, though the stock is still down 24% for the month.